Interpace Diagnostics MVPdX Lung Cancer Test

Interpace Diagnostics has launched a new lung cancer test, MVPdX, that  compares the mutational fingerprint of two or more sites of lung cancer to differentiate new primary lung tumors from recurrences or metastases. The assay is based on an analysis of loss of heterozygosity via a panel of microsatellite markers in proximity to 16 tumor suppressor genes.